AU2018269947B2 - Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors - Google Patents

Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors Download PDF

Info

Publication number
AU2018269947B2
AU2018269947B2 AU2018269947A AU2018269947A AU2018269947B2 AU 2018269947 B2 AU2018269947 B2 AU 2018269947B2 AU 2018269947 A AU2018269947 A AU 2018269947A AU 2018269947 A AU2018269947 A AU 2018269947A AU 2018269947 B2 AU2018269947 B2 AU 2018269947B2
Authority
AU
Australia
Prior art keywords
cancer
optionally substituted
group
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269947A
Other languages
English (en)
Other versions
AU2018269947A1 (en
Inventor
Zhuo Chen
Liyue HUANG
Liu Liu
Shaomeng Wang
Chao-Yie Yang
Dengyou ZHANG
Canhui ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2018269947A1 publication Critical patent/AU2018269947A1/en
Application granted granted Critical
Publication of AU2018269947B2 publication Critical patent/AU2018269947B2/en
Priority to AU2022200197A priority Critical patent/AU2022200197A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018269947A 2017-05-15 2018-05-15 Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors Active AU2018269947B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200197A AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506349P 2017-05-15 2017-05-15
US62/506,349 2017-05-15
PCT/US2018/032619 WO2018213211A1 (en) 2017-05-15 2018-05-15 Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200197A Division AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Publications (2)

Publication Number Publication Date
AU2018269947A1 AU2018269947A1 (en) 2019-12-19
AU2018269947B2 true AU2018269947B2 (en) 2021-10-14

Family

ID=62685119

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018269947A Active AU2018269947B2 (en) 2017-05-15 2018-05-15 Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
AU2022200197A Abandoned AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200197A Abandoned AU2022200197A1 (en) 2017-05-15 2022-01-13 Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Country Status (6)

Country Link
US (1) US11168082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3628044B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352284B2 (cg-RX-API-DMAC7.html)
CN (1) CN110914265B (cg-RX-API-DMAC7.html)
AU (2) AU2018269947B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018213211A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112119080B (zh) * 2018-05-15 2023-07-11 密歇根大学董事会 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje
HRP20251471T1 (hr) 2019-03-20 2026-01-02 Oryzon Genomics, S.A. Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat
US20220227763A1 (en) 2019-05-29 2022-07-21 Syngenta Crop Protection Ag Microbiocidal derivatives
CN112451671B (zh) * 2020-12-02 2021-11-02 武汉大学 KDM1A在抑制RNA病毒刺激下干扰素IFNβ表达中的应用
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
JP2025503099A (ja) * 2022-01-25 2025-01-30 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 ピリジン系誘導体、その製造方法及び使用
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
AU2023327925A1 (en) * 2022-08-22 2025-02-20 Redx Pharma Limited Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024208187A1 (zh) * 2023-04-03 2024-10-10 上海复星医药（集团）股份有限公司 氮杂芳基化合物及其作为lsd1抑制剂的用途
EP4784570A1 (en) * 2023-09-28 2026-08-05 The Regents of The University of Michigan Oxygenated heterocyclic lsd-1 inhibitors and related methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079521A2 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
KR20150024669A (ko) * 2013-08-27 2015-03-09 제일모직주식회사 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20160009720A1 (en) * 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016161282A1 (en) * 2015-04-03 2016-10-06 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016201266A1 (en) * 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
EP2295550A3 (en) * 2001-04-30 2011-12-14 Vertex Pharmaceuticals Incorporated Crystal structures of GSK-3beta protein and protein complexes and their use
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US20100130496A1 (en) * 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009029609A1 (en) 2007-08-27 2009-03-05 Wyeth Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP5744021B2 (ja) * 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CA3161836A1 (en) 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079521A2 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
KR20150024669A (ko) * 2013-08-27 2015-03-09 제일모직주식회사 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20160009720A1 (en) * 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016161282A1 (en) * 2015-04-03 2016-10-06 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016201266A1 (en) * 2015-06-11 2016-12-15 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1476063-00-9; STN Entry Date 18 November 2013; 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-1-[2-(1-pyrrolidinyl)ethyl]- *
MITKIN O D ET AL, TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (2001-02-25), vol. 57, no. 9, doi:10.1016/S0040-4020(00)01162-5, ISSN 0040-4020, pages 1827 - 1831 *
MOULD DANIEL P ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (2017-05-08), vol. 27, no. 14, doi:10.1016/J.BMCL.2017.05.018, ISSN 0960-894X, pages 3190 - 3195 *
PubChem Compound Summary for ClD 126554614 (4-(3-Fluorophenyl)-1H-pyrrolo[2,3-c]pyridine), National Center for Biotechnology Information, created on 22 April 2017 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/126554614> *
PubChem Compound Summary for ClD 66714572 (4-(1H-pyrrolo[2,3-c]pyridin-4-yl)aniline), National Center for Biotechnology Information, created on 30 Nov 2012 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/66714572> *
PubChem Compound Summary for ClD 68762939 (2-(1H-pyrrolo[2,3-c]pyridin-4-yl)benzonitrile), National Center for Biotechnology Information, created on 30 Nov 2012 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/68762939> *
PubChem Compound Summary for ClD 76847332 (5-Chloro-4-fluoro-1H-pyrrolo[2,3-c]pyridine), National Center for Biotechnology Information, created on 6 August 2014 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/76847332> *
PubChem Compound Summary for ClD 91345 (4-Chloroindole), National Center for Biotechnology Information, created on 26 March 2005 <URL: https://pubchem.ncbi.nlm.nih.gov/compound/91345> *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (1984-11-16), Database accession no. 17374-26-4 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2003-09-02), Database accession no. 577779-57-8 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2007-11-26), Database accession no. 955978-88-8 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2008-12-08), Database accession no. 1082041-85-7 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2008-12-11), Database accession no. 1083096-61-0 *

Also Published As

Publication number Publication date
AU2018269947A1 (en) 2019-12-19
JP7352284B2 (ja) 2023-09-28
CN110914265A (zh) 2020-03-24
AU2022200197A1 (en) 2022-02-10
WO2018213211A1 (en) 2018-11-22
US11168082B2 (en) 2021-11-09
JP2020519667A (ja) 2020-07-02
EP3628044A1 (en) 2020-04-01
US20200157091A1 (en) 2020-05-21
EP3628044B1 (en) 2023-11-22
CN110914265B (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
AU2022200197A1 (en) Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
US11045448B2 (en) Piperidines as covalent menin inhibitors
US20220411432A1 (en) Mdm2 protein degraders
US20210198237A1 (en) Piperidines as menin inhibitors
AU2017219627B2 (en) Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
US20240150360A1 (en) Small Molecule Degraders of CBP/p300 Proteins
WO2020103864A1 (en) Macrocyclic indoles as mcl-1 inhibitors
US10307407B2 (en) 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
AU2014249192A1 (en) BET bromodomain inhibitors and therapeutic methods using the same
US11944614B2 (en) Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
US20210115018A1 (en) Piperidine compounds as covalent menin inhibitors
US11046709B2 (en) Fused 1,4-diazepines as BET bromodomain inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40022861B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors